Crystal arthritis: Canakinumab relieves gout flares when treatment options are limited

Nature Reviews Rheumatology

Volumn 8, Issue 7, 2012, Pages 369-

  Onuora, Sarah ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CANAKINUMAB; INTERLEUKIN 1BETA ANTIBODY; TRIAMCINOLONE ACETONIDE;

ARTHRALGIA; CLINICAL EFFECTIVENESS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; GOUT; HUMAN; INFECTION; NOTE; PAIN ASSESSMENT; PRIORITY JOURNAL; SINGLE DRUG DOSE; TREATMENT CONTRAINDICATION; VISUAL ANALOG SCALE;

EID: 84863459923     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2012.90     Document Type: Note

References (1)

1. Original article Schlesinger, N. et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. J. Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2011-200908